WO1997002482A1 - Procede et dispositif pour la quantification volumetrique - Google Patents

Procede et dispositif pour la quantification volumetrique Download PDF

Info

Publication number
WO1997002482A1
WO1997002482A1 PCT/US1996/010977 US9610977W WO9702482A1 WO 1997002482 A1 WO1997002482 A1 WO 1997002482A1 US 9610977 W US9610977 W US 9610977W WO 9702482 A1 WO9702482 A1 WO 9702482A1
Authority
WO
WIPO (PCT)
Prior art keywords
reagent
apheresis sample
sample
apheresis
assay
Prior art date
Application number
PCT/US1996/010977
Other languages
English (en)
Inventor
Sam L. Woo
Thomas M. Baer
Joseph E. Baumgartner
Louis J. Dietz
Original Assignee
Biometric Imaging, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biometric Imaging, Inc. filed Critical Biometric Imaging, Inc.
Priority to AU65421/96A priority Critical patent/AU6542196A/en
Publication of WO1997002482A1 publication Critical patent/WO1997002482A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1433—Signal processing using image recognition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells

Definitions

  • the present invention relates generally to the field of chemical and microbiological assay techniques and more specifi- cally to a new and improved method of preparing an apheresis sample for cell classification and enumeration.
  • a major contaminant of blood derived transfusion products is leukocytes or white blood cells (WBC) from the donor.
  • the donor WBC may be contaminated with virus, such as cytomegalovirus and human immunodeficiency virus (HIV) , or the WBC may stimulate an immune response from the recipient.
  • virus such as cytomegalovirus and human immunodeficiency virus (HIV)
  • HIV human immunodeficiency virus
  • One method of reducing such effects is to use WBC reduction techniques, for example, cell filtering. Reduction techniques can reduce the concentration of WBC down to less than one cell per microliter. Detecting and monitoring leuko-reduced blood products for WBC contamination at such low levels is a pressing need for blood banks and the like.
  • the first technique is a laborious manual method using a Nagoette hemocytometer to count the number of WBC in a known volume.
  • the WBC are stained using a standard commercial stain called "Turk's solution.”
  • the sample is loaded into a Nagoette hemocytometer that can hold about one hundred microliters of sample.
  • An operator scans the hemocytometer using a standard microscope and counts the number of WBC observed in a known volume. This process takes about thirty minutes to an hour and is a very tedious method.
  • the second method uses a flow cytometer to count the number of WBC in the sample.
  • a known number of fluorescent beads or nucleated red blood cells from a chicken are added to a measured volume of sample.
  • a lysing agent is added to the sample to make the WBC permeable to a fluorescent intercalating dye, which is also added to the sample.
  • the intercalating dye preferentially binds to the deoxyribonucleic acid (DNA) in the nucleus of a WBC. The dye becomes much more fluorescent after binding to the nucleus. When excited by a laser, the WBC fluoresce significantly brighter than the solution of unbound intercalating dye (background) .
  • sample WBC concentration [Measured number of WBC1 * [Initial cone, of beads (or RBC) 1
  • Flow cytometers have the advantage of making rapid and accurate cell enumeration of different cells in a sample, but do not make direct accurate enumeration of cells per volume of whole blood. Flow cytometers present a sample of cells or particles before a light source in a linear flow path to meas- ure the interaction of the laser with each cell or particle. The flow path consists of a downward flowing stream of liquid into which the cells are released one at a time into the center of the flow path.
  • volumetric enumeration of apheresis samples without the problems associated with flow cytometers.
  • one known technique is to count all of the cells with a device such as a cell sorter to enumerate the total number of a certain subset of cells in a fixed volume of sample.
  • Another known system for cell enumeration is fluores- cent microscopy, which combines fluorescent labeling with microscopy technology. Since such systems use a microscope slide for sample interrogation, low event targets in large volume apheresis samples cannot be readily determined.
  • WBC leukocytes
  • the present invention provides a method and system for performing a sensitive and accurate white blood cell (WBC) enumeration in apheresis blood products.
  • WBC white blood cell
  • the present invention specifically discloses the assay chemistry, including reagents in a kit form, and procedure for low event leukocyte enumera- tion in platelet apheresis.
  • the basic data processing steps including sample interrogation, fluorescence emission data sampling, particle identification, cell classification and WBC enumeration are disclosed. This invention may also be useful for WBC enumeration in packed red blood cell products.
  • the present invention is unique in that it provides a method and system for enumerating WBC using intercalating dyes in a volumetric format.
  • a novel combination of assay reagents are used to lyse and permeabilize the cells, prevent clotting, and assisting the staining of the WBC DNA.
  • the cell recognition processor automatically sets certain gates for detecting the nucleated cells in the sample.
  • an adaptive threshold is used to follow changes in dye concentration and baseline (background) fluorescence.
  • a larger capillary is used, wherein the scanning instrument is focused on the lower portion of the capillary.
  • the WBC are stained with an intercalating dye. After incubation, the absolute number of cells are counted in a known volume.
  • the leukocyte depletion assay labels nucleated cells which are placed within a scan capillary, and allowed to settle. The capillary is scanned with a helium-neon (He-Ne) laser and the fluorescent response of the WBC in the capillary is measured.
  • He-Ne helium-neon
  • the cells are recognized from the fluorescent response using a cell identification algorithm.
  • the present invention includes an apparatus having a laser based optics module for scanning a capillary of an apher- esis sample containing an unknown amount of WBC.
  • Data sampling circuitry is provided to record fluorescent responses of the sample in the capillary.
  • the scanner and data sampling circuitry produce a plurality of channels of data, and a corresponding plurality of scanned images.
  • a processing system is coupled to the sampling circuitry, and includes resources to identify and enumerate the WBC which fluoresce in response to excitation by the laser.
  • a cartridge is provided for presenting a plurality of scan capillaries to the scanning instrument.
  • the cartridges are configured with application wells and pedestals for moving the apheresis sample into the scan capillaries for processing a known volume of fluorescently stained sample.
  • the intensity of the fluorescence of a target cell is determined by processing certain identified segments of data from the plurality of fluorescent responses based upon the expected characteristics of target WBC. For example, the segments are processed by defining a neighborhood of pixels for a candidate particle, wherein the neighborhood is larger than the expected size of the target cell. The pixels within the neighborhood are processed to compensate for background fluo ⁇ rescence and noise. An adaptive threshold on the fluorescence from the candidate particle is used to compensate for changes in dye concentration and baseline fluorescence.
  • an assay for enumerating target components in an apheresis sample in a fixed volume.
  • the apheresis sample is stained with a fluorescent compound configured to selectively bind to a target component of the apheresis sample.
  • a laser in the sample instrument is used to excite the fluorescent compound, while the data processor identifies, classifies and enumerates target leukocytes.
  • the present invention provides for an assay for enumerating leukocytes in a platelet apheresis sample in a fixed volume capillary.
  • a first reagent is added to the apheresis sample which is configured to stain DNA in leukocytes in the apheresis sample.
  • the first reagent includes a fluores ⁇ cent intercalating dye, such as a cyanine nucleic acid dye.
  • a second reagent is added to the apheresis sample to lyse the platelets, for example, polyoxyethylene ether.
  • the present invention includes a system for analysis of an apheresis sample, which uses a scanner configured to interrogate a sample with a light source to generate fluores ⁇ cent emission data.
  • a data processor is used to sample the fluorescent emission data to generate a plurality of pixel values.
  • the data processor also analyzes the pixel values to identify a candidate particle and a pixel neighborhood.
  • the fluorescence values for the pixel neighborhood are processed to classify the candidate particle as a leukocyte.
  • WBC enumera- tion includes comparing the fluorescent emission data to an adaptive intensity threshold and a slope gate.
  • a kit for use in an assay for enumerating leukocytes in a platelet apheresis sample.
  • the kit includes TO-PRO-3 intercalating dye configured to stain DNA in WBC.
  • a known amount of TRITON X-100 is included to lyse the platelets, while a quaternary ammonium salt is added to prevent the lysed platelets from aggregating.
  • the reagents are provided in a container, such as a vial, for incubating an apheresis sample containing leukocytes and platelets with the first, second and third reagents.
  • a cartridge having at least one scan capillary may be included in the kit.
  • FIGURE 1 is a system diagram of an optical scanner for use with the invention.
  • FIG. 2 is a side perspective view of a sample-filled capillary tube according to the invention, illustrating an illuminated columnar region from the excitation and emission beams, showing the scanner in schematic representation.
  • FIG. 3 is a side perspective view of a sample-filled capillary tube showing overlapping beam spots and an illumi ⁇ nated columnar region according to the invention.
  • FIG. 4 is a top perspective view of a sample-filled capillary tube, showing overlapping beam spots according to the invention.
  • FIG. 5 is a schematic representation of the optical scanning path according to the invention.
  • FIG. 6 is a schematic representation of a labeled cell suspension and the corresponding detector signal.
  • FIG. 7 is a perspective view in partial cross-section of a sample-filled capillary showing suspended dye particles within the apheresis sample, wherein the white blood cells have been allowed to settle to the bottom of the capillary.
  • FIG. 8 is an enlarged view of the portion in circle "8" of FIG. 7.
  • FIG. 9 schematically illustrates an organization of fluo- rescent data pixels into a neighborhood generated by sampling and storing the output of the scanner of FIG. 2.
  • FIG. 10 is a graph illustrating the emission spectra of
  • FIG. 11 illustrates a cell classification graph used for classifying cells based on two channels of data.
  • FIGS. 12B and 12B together make up a flow chart for the basic data processing method.
  • FIG. 13 is a flow chart illustrating the generation of background indices.
  • FIG. 14 is a flow chart of the process used for detecting particles from the fluorescent data.
  • FIG. 14A is a pixel diagram showing the perimeter and adjacent pixel comparison of FIG. 14.
  • FIG. 15 is a flow chart for the process used for classifying cells.
  • FIG. 16 is a graph showing the relationship of interca ⁇ lating dye concentration to the fluorescent units exhibited by a target cell and by the background fluorescence from a platelet apheresis sample.
  • FIG. 17 is a graphical representation fluorescent units exhibited for the background and a target cell for a plurality of assay configurations.
  • FIG. 18 is a perspective view of an assembled assay cartridge constructed with dual capillaries.
  • FIG. 19 is an exploded perspective view of the assay cartridge of FIG. 18.
  • FIG. 20 is a perspective view of an assembled assay cartridge constructed with four capillaries.
  • FIG. 21 is an exploded perspective view of the assay cartridge of FIG. 20. DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • the present invention is embodied in a method and system for performing sensitive and accurate white blood cell (WBC) enumeration in apheresis blood products.
  • the present invention includes the assay chemistry, including reagents in a kit form, and procedure for low event leukocyte enumeration in platelet apheresis.
  • the basic data processing steps including sample interrogation, fluorescence emission data sampling, particle identification, cell classification and WBC enumeration are disclosed. This invention may also be useful for WBC enumeration in packed red blood cell products.
  • the present invention includes an optics module or scanner 25 including a laser 27, such as a helium neon (He-Ne) laser, which generates an excitation beam 28 that impinges on a glass plate 29.
  • a laser 27 such as a helium neon (He-Ne) laser
  • He-Ne helium neon
  • the glass plate reflects a significant portion of the laser beam to a power monitor 30 which measures the power output of the laser.
  • the portion of the excitation beam 32 that is passed through, rather than reflected by, the glass plate is directed through a laser line filter 33 and then to a first spectral dispersion device 34, which may be, for example, a dichroic mirror, a prism, or a grating.
  • the spectral dispersion device reflects the excitation beam which, in the case of a He-Ne laser, has a wavelength of approximately 633 nanometers.
  • the excitation beam is then directed to a first mirror 35 and through a right angle prism 36 to a scan assembly 40.
  • the scan assembly 40 comprises a galvanometer 41 attached to a galvo mirror 42, a first lens 43, a second lens 44, and an objective lens 45.
  • the passed portion of the excitation beam 32 travels from the galvo mirror through the first lens and then through the second lens. From the second lens, the excitation beam is directed through the objective lens so that a focal spot of the beam may impinge upon a transparent capillary tube 50, having an upper surface 51.
  • the capillary contains the sample to be analyzed, which includes target WBC in platelet apheresis mixed with an excess of an intercalating dye used to stain the WBC.
  • the excitation beam 32 impinging upon the upper surface 51 of the capillary 50 traverses the wall and illuminates a region of the sample causing fluorescent emission from the sample.
  • Light collection occurs in an epi-illumination manner.
  • the emitted fluorescence is collected by objective lens 45 and directed back, as retrobeam 53, through scan assembly 40.
  • the objective lens has a central portion for passage of the excitation beam and uniform depth of focus of the excitation beam through bottom one-third of the capillary tube. Because fluorescent emission is over a very wide angle, represented by retrobeam rays 54 and 54, fluorescent collection occurs over a wider portion of the objective lens.
  • the retrobeam 53 travels from scan assembly 40 to the right angle prism 36 to the first mirror 35 and the first spectral dispersion device 34.
  • the retrobeam has a spectral range which encompasses different wavelength than the excitation beam 28 and may there ⁇ fore be directed differently than the excitation beam by the same optical components that direct the excitation beam to the scan assembly.
  • the retrobeam is transmitted through the first spectral dispersion device and through a bandpass filter 61 to a second mirror 62 where it is directed through a colli ⁇ mating lens 63.
  • the retrobeam is then selectively passed through a spatial filter 64 and into a detection assembly 70.
  • the spatial filter has a predetermined pinhole aperture of a diameter that permits passage of only that fluorescence emission from a columnar region 60 defined by the illuminated segment within the capillary tube 50.
  • any light having the wavelength of the excitation beam 32 will be removed from the retrobeam 53, for example,- light from the excitation beam reflected by the upper surface 51 of the capillary 50 along the path of the retrobeam. Such light will either be directed by the first spectral dispersion device 34 away from the path of the retrobeam and back toward the laser 27 or will be removed by the band bass filter 61.
  • the retrobeam is thereby purged of reflected excitation light.
  • the retrobeam is focused by the collimating lens 53 through the pinhole aperture of the spatial filter 54, which acts to eliminate from the retrobeam any light other than fluorescent emissions from a defined region 60 of the sample within the capillary.
  • the detection assembly 70 comprises two detection channels, each having a detector 71, 72 which amplifies the fluorescent signal of the retrobeam 53.
  • the detector is a light measuring device, such as a photomulti- plier tube (PMT) or photodiode.
  • a second spectral dispersion device 73 is positioned between the spatial filter 64 and the detectors to split the retrobeam as a function of its wave ⁇ length.
  • a first beam 77 of one range of wavelength is impinged upon the first detector 71/ and a second beam 78, having another wavelength range, is impinged upon the second detector 72.
  • Each detector is in electronic communication with a data processor 75, which converts analog signals from the detectors to digital data representative of the retrobeam' s fluorescence intensity.
  • the spatial filter 64 is configured with a pinhole aperture that collects light over a large numerical aperture, but confines the depth of detection to a defined portion 60 of the interior depth dimension of the capillary tube 50.
  • the objective lens 45 has been configured to focus the excitation laser beam 32 to provide a uniform illumination waist or columnar region 81 along the lower one-third (one hundred microns) of the capillary tube. Similarly, only the fluorescence from the sample in the bottom one-third of the capillary is focused from the retrobeam 53 and impinged upon the detectors 71, 72.
  • the capillary tube 50 is a transparent sample holder of known dimensions, preferably made of optics quality glass or acrylic.
  • the capillary tube preferably has a rectangular cross-section with a shorter dimension defining an interior depth of two hundred to four hundred microns and a longer dimension defining a width of one to three millimeters.
  • the length of the capillary tube is chosen to provide a desired volume of the sample to be processed.
  • the beginning and ending longitudinal points of the scan in a direction along the length of the capillary tube define the precise volume of the sample scanned.
  • the present invention it is important to use a sufficiently large sample volume to ensure detection of WBC in sufficient number to make the results statistically signifi ⁇ cant.
  • a capillary being three hundred microns deep, three millimeters wide and forty milli ⁇ meters long provides optimal scanning characteristics.
  • the diameter of the columnar region 81 defined by the excitation beam 32 is preferably ten to fifteen microns, or about the same size as a target cell.
  • the cross section of the columnar region or waist is referred to herein as the "beam spot.”
  • the excitation beam spot 80 (shown for illustration purposes along the upper surface 51 of the capillary 50) is moved to a new position to illuminate an adjacent columnar region 82 at the lower one-third of the capillary.
  • the excitation columnar region is moved a distance that is only a fraction of the beam spot diameter, so that each illuminated columnar region 81 partially overlaps adjacent illuminated columnar region 82.
  • the optical scanning of the capillary continues in this manner of illuminating and fluores- cently exciting a region from which fluorescent emission is detected and recorded, then is moved slightly to illuminate a new columnar region and to repeat the data collection process.
  • the scanning assembly 40 moves the excitation beam spot
  • the transverse scan begins at point 88 inside a first edge 91 of the upper surface 51 of the capillary and ends at a point 89 inside the second edge 92 of the capillary upper surface.
  • FIG. 5 shows a schematic representation of scan path 95 from above capillary tube 50, according to the preferred embod ⁇ iment of the present invention.
  • the excitation beam spots are moved along the scan path in a transverse direction from inside the first edge 91 to inside the second edge 92, then returned to the first edge to follow a closely-spaced and overlapping parallel path in the transverse direction.
  • the scanning starts and ends one millimeter inside the capillary edges.
  • the scanning process is repeated contiguously so that the scan covers a desired distance along the longitudinal axis, of the capillary tube. In this manner, fluorescence emission occurs and is detected from any chosen length of the capillary tube.
  • the volume of the sample scanned is determined by multiplying the depth of the capillary times the distance of the transverse scans (point 88 to 89) times the longitudinal distance scanned.
  • the fluorescent signal from the detectors 71, 72 and stored by the data processor 75 may be represented graphically in a plot 96 of fluorescent units (Y- axis) versus time (X-axis) .
  • the background level 97 of fluorescence is caused by unbound dye 101 in the sample. This background level will not be constant and is disturbed by artifacts, such as clumped platelets and uneven dispersion of the dye particles.
  • Each WBC 100 is represented by a fluores ⁇ cent event 98.
  • the method of the present invention does not require removal of unbound intercalating dye.
  • the assay chemistry of the present inven ⁇ tion optimizes the ratio of the peak fluorescence from a cellular event versus the background level fluorescence.
  • the capillary 50 is shown with a partial cutaway of the capillary wall 52, demonstrating the location of the target WBC 100 in the sample of platelet apheresis 102.
  • the capillary is shown in a stasis preferred just prior to interrogation by the scanner 25.
  • the sample has been permitted to stand after vortexing, allowing the heavier WBC to settle near the bottom 103 of the capillary.
  • the unbound dye particles 101 remain suspended in the platelet apheresis within the volume of the capillary.
  • the optics module 25 allows transverse and longitudinal scanning of the laser beam 32 across the sample capillary 50.
  • the scan assembly 40 includes a galvanometer 41 driven mirror 42 which rotates a few degrees back and forth in a rapid fashion at about 20 - 200 Hz (peak-to-peak 6-12°) .
  • the excitation beam is deflected by the galvanometer mounted mirror to the first lens 43, through the second lens 44 and through the objective lens 45 to the upper surface 51 of the capillary.
  • the two scan assembly lenses 43, 44 are configured with equal focal lengths and are separated along the optical path by twice their focal length. In addition, the lenses have overlapping focal planes. Similarly, the distance between the second lens 44 and the objective lens 45 must be precisely controlled so that the excitation beam 32, as it is displaced by the galvanometer driven mirror 42, appears to be rotating about a virtual point directly in front of the scanning assembly objective.
  • the transverse scan path 95 is about one millimeter long. This provides two hundred-fifty samples along each scan path. For a forty millimeter long capillary, with scan lines separated by four microns, about ten thousand scan lines are collected for each apheresis sample.
  • the data processor 75 is configured to sample and store in data memory each fluorescent data value (pixel 105) from the detectors 71, 72 at a rate which creates a data sampling array representing a four micron transverse or longitudinal displace ⁇ ment of the excitation beam spot 80.
  • FIG. '9 illustrates a seven-by-seven array of pixels, referred to herein as a
  • neighbor 110.
  • pixel of row 1, column 1 is found in the upper left hand corner.
  • pixel of row 1, column 7 is found in the upper right hand corner.
  • pixel of row 4, column 4 is found in the center of the neighborhood of pixels.
  • pixel of row 7, column 7 is found in the lower right hand corner.
  • FIG. 9 also illustrates the size of the excitation laser beam spot 80 relative to the pixel 105 dimensions, wherein oversampling occurs.
  • the beam spot has a diameter of about ten microns.
  • the first excitation beam spot 111 excites a region of ten microns in diameter for the pixel at row 7, column 1.
  • a second beam spot 112 illuminates a region ten microns in diameter which substantially overlaps with the first beam spot for row 7, column 1.
  • the adjacent third beam spot 113 for row 7, column 2 substantially overlaps with the first beam spot and the second beam spot in column 1.
  • retrobeam 83 is comprised of fluorescence from the bound and unbound intercalating dye in the illuminated sample.
  • the retrobeam is directed to a spectral dispersion device 73 which separates the fluorescence into two beams.
  • the first beam 77 contains fluorescent emissions with wavelengths less than the cutoff point of the spectral dispersion device.
  • the second beam 78 contains fluorescent emissions with wavelengths greater than the cutoff point of the spectral dispersion device.
  • the first resultant beam is directed to the first detector 71 (channel 0)
  • the second resultant beam is directed to the second detector 72 (channel 1) .
  • a portion of the fluorescence from the dye will be directed into each of the channels.
  • FIG. 10 depicts the cutoff curve 115 for a dichroic mirror which splits the fluorescent wavelengths at approximately 684 nano- meters.
  • Suitable intercalating dyes include monomeric cell- impermeant nucleic acid stains. Especially useful are membrane-impermeant cyanine nucleic acid dyes which are excitable by a He-Ne laser at about 633 nanometers.
  • One such intercalating dye is a benzothiazolium-4-quinolinium dye available under the trade name TO-PRO-3 from Molecular Probes, Eugene, OR.
  • TO-PRO-3 has an absorption maximum at 642 nano ⁇ meters and an emission maximum of 661 nanometers.
  • TO-PRO-3 has an emission spectrum from about 600 nanometers to about 800 nanometers, as shown by line 117 in FIG. 10.
  • FIG. 11 represents a graph of fluorescent responses for WBC 100 and other sample artifacts 120.
  • the WBC may be differentiated by comparing the absolute and relative responses from the two detectors (PMT) 71, 72. One differentiation is based comparing the fluorescent intensity from the first detector I 0 (x-axis) to a minimum adaptive intensity threshold 122.
  • the adaptive threshold is derived from the fluorescent intensity value of the baseline or background value, which is a function of dye concentration. See FIGS. 16 and 17 and associated text herein. Any fluorescent particle or artifact which does not generate the minimum fluorescent response relative to the background intensity is disregarded, and is not counted as a WBC.
  • Another differentiation of the raw fluorescent data is based on comparing the fluorescent intensity from the first detector I 0 relative to the fluorescent intensity from the second detector Ii- This comparison is accomplished by comparing the ratio of the intensities to a empirically determined calibration slope 124.
  • a high tolerance slope 125 and a low tolerance slope 126 around the calibration slope brackets the acceptable range of fluorescent values from the two detectors for discriminating a WBC from other fluorescent artifacts in the sample. Any fluorescent particle or artifact which does not generate relative values of the channel 0 intensity I 0 and channel 1 intensity I within the tolerance around the calibration slope is disregarded, and is not counted as a WBC.
  • FIGS. 12A and 12B the data processor initiates WBC identification and enumeration, FIGS. 12A and 12B.
  • Cell identification is performed by software programming stored in the memory of the data processor.
  • WBC discrimination includes analysis of the fluorescent data derived from the detection assembly 70. The linear regression technique used to discriminate the fluorescent data stored for the two channels is described in copending U.S. application serial number 08/236,645 (hereinafter "Sitzo et al. ”) and is incorporated herein by reference.
  • Sitzo et al. The linear regression technique used to discriminate the fluorescent data stored for the two channels is described in copending U.S. application serial number 08/236,645 (hereinafter "Sitzo et al. ”) and is incorporated herein by reference.
  • cell classification analysis is performed on a seven-by-seven neighborhood of pixels centered on each target cell which is detected using the method of FIGS. 12A and 12B.
  • FIG. 13 illustrates a method for processing background noise indices to define the tolerances 125, 126 around the calibration slope 124 in FIG. 11 within which the fluorescent response measured for a neighborhood will be characterized as a WBC.
  • This background index is recalculated for each neighborhood (block 209) . The process is carried out for the data from both detectors 71, 72 (channels) to achieve two separate background noise indices.
  • FIG. 14 illustrates the algorithm for detecting a particle (block 211) , which may be a candidate cell for enumeration.
  • the particle detection algorithm uses the average or sum of the fluorescent data stored for each pixel (block 400) .
  • a five-by-five pixel map (block 401) surrounding each pixel is tested (block 402) . The test ensures that the fluo ⁇ rescent values for the particle match the expected intensity profile for a WBC, and are not indicative of noise or other non-WBC artifacts.
  • the cell detection test first determines whether the center pixel 410 fluorescent intensity value minus an adaptive intensity threshold value is greater than each of the perimeter pixel 412 fluorescent intensity values. The test also determines whether the absolute value of the center pixel fluorescent intensity value is greater than each of the adjacent pixel 414 values. If either of these tests are negative, i.e., center pixel not greater, then the particle is disregarded and not counted as a WBC. If both tests are satisfied (block 403) , then the location of the center pixel in the data array (capillary position) is recorded. In addition, a seven-by-seven pixel map, or neighborhood, surrounding the center pixel is saved
  • FIG. 15 illustrates the enhanced method for processing WBC fluorescent data in an apheresis sample.
  • Cell classifica- tion according to a preferred embodiment of this invention is similar to that found in Sizto et al. , though it differs in several material ways.
  • the method includes retrieving (block 500) the seven-by-seven neighborhood of fluorescent data values stored for each particle, as described herein (block 213) . Additional parameters are extracted from the particle neighbor ⁇ hood which describe the particle in geometric or morphologic terms, such as, but not limited to, area, radius, circularity, etc. With reference to FIG. 11 and specifically to the steps outlined in FIG. 15, particles are classified as to cell type.
  • the coefficient of regression (r) is compared to a threshold (K 0 ) disclosed in Sizto et al. (block 501) . If the coefficient is not greater than the threshold, then the parti- cle is disregarded and not enumerated as a WBC (block 507) .
  • an adaptive intensity threshold 122 based on the intensity of the channel 0 baseline is used to qualify cell intensity (block 502) .
  • This second test reduces or eliminates any sensitivity the method may have to variations in baseline or median particle intensity.
  • the particle intensity (I 0 ) from channel 0 (first detector 71) which is above the baseline (background) is compared to an adaptive threshold (K ⁇ ) proportional to the intensity of the channel 0 baseline. If the particle intensity is not greater than the intensity threshold, then the particle is disregarded and not enumerated as a WBC (block 507) .
  • the method of the present invention uses a symmetric region 125, 126 around the calibration slope 124 to include candidate WBC particles and exclude noise particles (block 503) .
  • the absolute difference between the channel 1 (second detector 72) particle intensity above baseline (I x ) and the channel 0 particle intensity above baseline (I 0 ) projected onto channel 1 through the calibration slope (J-) is compared to the adaptive threshold proportional to the mode of the channel 0 baseline variation (K 2 ) . If the channel 1 brightness is not within the slope gate, then the particle is disregarded and not enumerated as a WBC (block 507) .
  • the last criterion for classification is based on the geometric properties of the candidate particle (block 504) .
  • the channel 0 particle area (A 0 ) must be greater than a first empirical threshold (K 3 ) and less than a second empirical threshold (K 4 ) .
  • the channel 0 particle area (A 0 ) is defined as the number of pixels in the seven-by-seven neighbor ⁇ hood with channel 0 intensity greater than or equal to a minimum percentage, for example, one-third, of the intensity of the pixel with the greatest intensity in the neighborhood. If the particle area is not within the empirical thresholds, then the particle is disregarded and not enumerated as a WBC (block 507) .
  • the identified particle must satisfy four criteria to be classified as a WBC: (block 501) r > K 0 (block 502) I 0 > K x (block 503) I Ii - j I ⁇ K 2 (block 504) K 3 ⁇ A 0 ⁇ K 4 .
  • the fluorescent emission of a WBC stained with a fluorescent intercalating dye may be plotted against the concentration of the dye in the initial incubating solution.
  • Most cyanine nucleic acid stains will exhibit a fluorescent curve 130 which has a high-noise-ratio region 132 followed by a linear region 134.
  • the linear region ends at a non-linear region 136 finalizing in a flattened saturation portion 138 of the curve.
  • An aspect of the present invention is to use the interca ⁇ lating dye in a concentration in the linear region of the curve.
  • Using a dye concentration in the linear range provides a significant difference between the fluorescent units exhib ⁇ ited by the white blood cell stained with the intercalating dye and the corresponding background fluorescence 140 exhibited by the unbound intercalating dye in the solution.
  • the background fluorescence exhibits a linear relationship to the initial dye concentration in the incubating solution. It has been found for certain cyanine nucleic acid stains, such as TO-PRO-3 (benzothiazolium-4-quinolinium) , that a concentration of 0.2 micromolar to 1.0 provides a preferred ratio of WBC fluorescence to background fluorescence.
  • the target cell fluorescence significantly stands out over (greater magnitude) the background fluorescence.
  • Four curves are shown to demonstrate the relative difference between the background fluorescence and the peak fluorescence from a WBC stained with an intercalating dye.
  • the preferred difference is a function of the scanning optics and cell identification software.
  • a ratio of about 5:1 is preferable.
  • the depth of the capillary 50 may be configured to adjust the ratio of target cell fluorescence to background fluorescence.
  • Curve A exemplifies the background fluorescence 141 at a very low level, while the target cell fluorescence 142 is also at a low level. Such a combination is unacceptable, because there is an insufficient difference between the target cell fluorescence and the background fluorescence. Moreover, there is a high noise-to-signal ratio, wherein the noise (shot, thermal, etc.) dominates the fluorescent signal from the background, blurring the distinction between the target cell fluorescence and the background fluorescence. Curve A is indicative of too low a dye concentration in the incubating solution.
  • Curve B demonstrates the condition where the dye concen ⁇ tration reaches the saturation point 138 for maximum WBC peak fluorescence 144.
  • the corresponding background fluorescence level 145 is too high to readily distinguish the WBC peak fluorescence.
  • the ratio of the target cell fluorescence to background fluorescence is too low.
  • Curve B is indicative of excessively high dye concentration in the incubating solution.
  • Curve C demonstrates the condition where the dye concentration approaches the saturation point 138 for maximum WBC peak fluorescence 144, but remains in the linear range 134.
  • the peak fluorescence 146 of a target cell is near its optimum point, but the background fluorescence 145 is unaccept- ably high with respect to the peak fluorescence.
  • Curve C is indicative of configuring the capillary 50 too deep for the concentration of intercalating dye used in the incubating solution.
  • Curve D demonstrates the condition where the incubating solution dye concentration is properly chosen in the linear range 134, and the depth 58 of the capillary 50 is chosen to optimize the background fluorescence 147.
  • the peak fluorescence 148 of a target cell is near its optimum point, while the background fluorescence is sufficiently low.
  • the incubating solution dye concentration and capil ⁇ lary depth are configured to provide a WBC peak fluorescence near the saturation level, while exhibiting a background fluo ⁇ rescence level about one fifth the peak fluorescence.
  • using a three hundred micron deep capillary and a TO-PRO-3 dye concentration of about 0.9 micromolar provides an approximate ratio of WBC fluorescence to background fluorescence of 5:1.
  • the present invention of mixing the intercalating dye concentration to provide a fluorescence of a WBC in the linear range, while configuring a optimum depth capillary to provide the desired ratio of peak to background fluorescence was certainly not known to those of ordinary skill in the art .
  • Another aspect of the present invention is to enhance the activity of the intercalating dye by permeabilizing the target cell membrane with a surfactant, detergent or other mild lysing agent.
  • a surfactant detergent or other mild lysing agent.
  • One such compound is polyoxyethylene ether, available under the trade name TRITON X-100 from Bio-Rad, Richmond, CA.
  • the lysing agent is used in sufficient concentration in the sample to adequately lyse the platelets. This allows the target WBC to settle to the bottom of the capillary, within the focal range of the scanning instrument (one hundred microns) .
  • platelet lysing reduces fluorescent scatter and other optical interference from the platelets.
  • the lysing agent should be selected and provided in a concentration that will not lyse the target cells, here the WBC.
  • One of the aspects of the present invention is to con ⁇ figure the concentration of the sample chemistry, including the concentration of TRITON X-100, such that after the period of incubation the cell membranes of the WBC are sufficiently permeabilized or weakened to allow the intercalating dye TO- PRO-3 to enter the WBC and stain the cell DNA.
  • the optimum concentration range of TRITON X-100 is 50.0 millimolar (mM) to 200.0 mM, and preferably 90.3 mM. At such a concentration, the WBC are sufficiently permeabilized, but will not lyse for at least four hours.
  • Another aspect of the assay chemistry of the present invention is to add a quaternary ammonium salt to the sample in sufficient concentration to prevent agglutination or similar aggregation of platelet particles after lysing.
  • a quaternary ammonium salt having suitable surface active properties is dodecyltrimethylammonium bromide, available from Aldrich, Milwaukee, WI .
  • the quaternary ammonium salt may be dissolved in an isotonic diluent, for example, dimethyl sulfoxide (DMSO) also available from Aldrich, Milwaukee, WI .
  • DMSO dimethyl sulfoxide
  • kits including a dispensing vial.
  • the intercalating dye TO-PRO-3
  • detergent TRITON X- 100
  • quaternary ammonium salt dodecyltrimethylammonium bromide
  • DMSO diluent
  • a kit may comprise the reagent chemistry and a sample cartridge having at least one scan capillary and application well.
  • a pipette may be supplied with the kit to remove a desired amount of the platelet apheresis sample from its container and to dispense the reagent-apheresis mixture to the application well of the cartridge.
  • a cartridge 150 is provided to present a bio ⁇ logical sample for analysis by an imaging or scanning instru ⁇ ment.
  • the cartridge uses one or more glass or acrylic capil ⁇ laries 160 and adjacent application wells 165 to present an aliquot of incubated sample for interrogation by the instrument optics. Since a predetermined aliquot of sample is drawn from the application well by each capillary, there is no need to meter the sample into the application wells.
  • a practical and cost effective cartridge and assay process is provided which eliminates the need for complicated and costly fluidics frequently found in prior art cartridges.
  • Such a cartridge is especially useful with fixed volume assays.
  • the cartridge 150 comprises three molded plates 152, 154 and 156, preferably made of a plastic or the like, such as acrylonitrile butadiene styrene (ABS) , polystyrene or polymethyl methacry ⁇ late.
  • ABS suitable for manufacture of a cartridge incorpor- ating the present invention may be purchased from BASF Corp. of Wyandotte, MI under the trademark "TERLUX 2802 TR. " The ABS plates are fused together, preferably by ultrasonic welding, as shown in FIGS. 18 and 20.
  • the cartridge may be configured with a plurality of scan capillaries, for example, two capillaries (FIGS. 18, 19) or four capillaries (FIGS. 20, 21) .
  • the top plate 152 is configured with a groove or slot 162 to hold each capillary 160.
  • the capillary may be press fit or glued into the slot.
  • An application well 165 is configured adjacent one end of the capillary slot so as to provide a res- ervoir of sample to the capillary.
  • the application well is further configured with a pedestal 158 for directly applying the sample droplet. The sharp edges of the pedestal act as a stop junction, preventing the sample from being drawn under the capillary into the slot. The remainder of the application well forms a moat around the pedestal.
  • the top plate and middle plate 154 are further configured with registration markers 167 to ensure proper alignment of the cartridge within the scanning instrument.
  • the middle plate is also configured with an arcuate handle portion 170 for ease of insertion of the cartridge into the scanning instrument. All three cartridge plates are preferably configured in a triangular • shape so as to fit symmetrically within a round rotatable platter in the scanning instrument .
  • a cartridge with a rectangular or similar shape may be suitable for other instrument configurations.
  • a volume of 50.0 ⁇ L of the mix was then loaded into a rectangular glass capillary with the internal dimensions of 0.3 millimeters (mm) thick, 3.0 mm wide and 50.0 mm in length that was mounted on an scanning cart-ridge.
  • the cartridge was loaded into a scanning instrument of the present invention and the sample was then analyzed using the method of the present invention.
  • the method included delaying the interrogation of the sample in the scanning capillary for fifteen minutes. The delay permitted the stained cells to settle to the bottom of the capillary.
  • the depth of field of the scanning instrument was configured to be less than the thickness of the capillary, i.e., 0.1 mm.
  • the instrument was focused at a region to best detect the stained cells, i.e., at the bottom one third of the capillary.
  • the capillary was then scanned over three minutes and the WBC counts were obtained.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Signal Processing (AREA)
  • Dispersion Chemistry (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne l'énumération des globules blancs dans les produits à aphérèse réduite des leucocytes au moyen d'un laser rouge à hélium et au néon utilisé pour induire la fluorescence dans les cellules intercalaires nucléées marquées avec un colorant dans des échantillons placés dans des tubes capillaires rectangulaires de précision. On fait incuber les échantillons d'aphérèse avec un seul tensioactif qui permet au colorant intercalaire de pénétrer à l'intérieur des globules blancs. Un instrument de balayage balaie, identifie et énumère les globules blancs dans l'échantillon d'aphérèse. Le système utilise un seuil adaptatif d'intensité pour identifier les particules cibles fluorescentes. Des réactifs sont utilisés pour la lyse des plaquettes sanguines ou des globules rouges dans le produit d'aphérèse. Un sel d'ammonium quaternaire est ajouté pour empêcher l'agglomération. L'échantillon est présenté à l'instrument de balayage dans des tubes capillaires rectangulaires en verre ayant une profondeur de 300 microns. Les réactifs et la cartouche sont fournis sous forme de kit.
PCT/US1996/010977 1995-06-30 1996-06-27 Procede et dispositif pour la quantification volumetrique WO1997002482A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65421/96A AU6542196A (en) 1995-06-30 1996-06-27 Volumetric cell quantification method and system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49750995A 1995-06-30 1995-06-30
US08/497,509 1995-06-30

Publications (1)

Publication Number Publication Date
WO1997002482A1 true WO1997002482A1 (fr) 1997-01-23

Family

ID=23977164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010977 WO1997002482A1 (fr) 1995-06-30 1996-06-27 Procede et dispositif pour la quantification volumetrique

Country Status (2)

Country Link
AU (1) AU6542196A (fr)
WO (1) WO1997002482A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2840992A1 (fr) * 2002-06-18 2003-12-19 Hemosystem Procede de denombrement et/ou d'identification morphologique de leucocytes en phase solide
US6667177B1 (en) * 1997-11-11 2003-12-23 Kowa Company, Ltd. Method for counting leukocytes and apparatus for counting leukocytes
FR2877092A1 (fr) * 2004-10-26 2006-04-28 Commissariat Energie Atomique Methode de mesure relative du rendement quantique de fluorescence de colorants en solution
EP1701150A1 (fr) 2005-03-11 2006-09-13 Hemocue AB Dénombrement de leucocytes
WO2008010761A1 (fr) 2006-07-19 2008-01-24 Hemocue Ab appareil de mesure, procédé et programme informatique
EP1947441A2 (fr) * 2007-01-17 2008-07-23 Hemocue AB Appareil pour déterminer les positions d'objets contenus dans un échantillon
WO2009091925A2 (fr) * 2008-01-16 2009-07-23 Life Technologies Corporation Système et procédé pour matériel de concentration acoustique et mises en œuvre
US7837040B2 (en) 2007-04-09 2010-11-23 Los Alamos National Security, Llc Acoustic concentration of particles in fluid flow
EP2267444A1 (fr) * 1998-03-07 2010-12-29 Wardlaw Partners LP Détermination de la formule leucocytaire et du nombre de reticulocytes
WO2012059784A1 (fr) 2010-11-03 2012-05-10 Reametrix Inc Procédé et dispositif de mesure de fluorescence d'échantillons
US8846408B2 (en) 2007-04-02 2014-09-30 Life Technologies Corporation Particle analyzing systems and methods using acoustic radiation pressure
US8863958B2 (en) 2007-04-09 2014-10-21 Los Alamos National Security, Llc Apparatus for separating particles utilizing engineered acoustic contrast capture particles
US8932520B2 (en) 2007-10-24 2015-01-13 Los Alamos National Security, Llc Method for non-contact particle manipulation and control of particle spacing along an axis
US9038467B2 (en) 2007-12-19 2015-05-26 Los Alamos National Security, Llc Particle analysis in an acoustic cytometer
US9074979B2 (en) 2004-07-29 2015-07-07 Los Alamos National Security, Llc Ultrasonic analyte concentration and application in flow cytometry
US9494509B2 (en) 2006-11-03 2016-11-15 Los Alamos National Security, Llc System and method for measuring particles in a sample stream of a flow cytometer using low-power laser source
US20210181085A1 (en) * 2017-10-26 2021-06-17 Essenlix Corporation Rapid measurement of platelets

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521518A (en) * 1980-06-16 1985-06-04 Coulter Electronics, Inc. Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes
US5009503A (en) * 1988-06-13 1991-04-23 Hipple Cancer Research Corporation Automated capillary scanning system
US5321130A (en) * 1992-02-10 1994-06-14 Molecular Probes, Inc. Unsymmetrical cyanine dyes with a cationic side chain
USD366938S (en) * 1994-09-02 1996-02-06 Biometric Imaging, Inc. Cartridge for processing laboratory samples
US5547849A (en) * 1993-02-17 1996-08-20 Biometric Imaging, Inc. Apparatus and method for volumetric capillary cytometry

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521518A (en) * 1980-06-16 1985-06-04 Coulter Electronics, Inc. Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes
US5009503A (en) * 1988-06-13 1991-04-23 Hipple Cancer Research Corporation Automated capillary scanning system
US5321130A (en) * 1992-02-10 1994-06-14 Molecular Probes, Inc. Unsymmetrical cyanine dyes with a cationic side chain
US5547849A (en) * 1993-02-17 1996-08-20 Biometric Imaging, Inc. Apparatus and method for volumetric capillary cytometry
USD366938S (en) * 1994-09-02 1996-02-06 Biometric Imaging, Inc. Cartridge for processing laboratory samples

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VOX SANG., 1990, Vol. 59, DZIK et al., "Flow-Cytometric Method for Counting Very Low Numbers of Leukocytes in Platelet Products", pages 153-159. *
VOX SANG., 1992, Vol. 62, PIETERSZ et al., "Comparison of Five Different Filters for the Removal of Leukocytes from Red Cell Concentrates", pages 76-81. *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667177B1 (en) * 1997-11-11 2003-12-23 Kowa Company, Ltd. Method for counting leukocytes and apparatus for counting leukocytes
EP2267444A1 (fr) * 1998-03-07 2010-12-29 Wardlaw Partners LP Détermination de la formule leucocytaire et du nombre de reticulocytes
WO2003107005A1 (fr) * 2002-06-18 2003-12-24 Hemosystem Procede de denombrement et/ou d’identification morphologique de leucocytes en phase solide
FR2840992A1 (fr) * 2002-06-18 2003-12-19 Hemosystem Procede de denombrement et/ou d'identification morphologique de leucocytes en phase solide
US10537831B2 (en) 2004-07-29 2020-01-21 Triad National Security, Llc Ultrasonic analyte concentration and application in flow cytometry
US9074979B2 (en) 2004-07-29 2015-07-07 Los Alamos National Security, Llc Ultrasonic analyte concentration and application in flow cytometry
FR2877092A1 (fr) * 2004-10-26 2006-04-28 Commissariat Energie Atomique Methode de mesure relative du rendement quantique de fluorescence de colorants en solution
WO2006092475A1 (fr) * 2004-10-26 2006-09-08 Commissariat A L'energie Atomique Methode de mesure relative du rendement quantique de fluorescence de colorants en solution
EP1701150A1 (fr) 2005-03-11 2006-09-13 Hemocue AB Dénombrement de leucocytes
JP4642893B2 (ja) * 2005-03-11 2011-03-02 ヘモク アクチボラゲット 白血球の体積当たりの計数を行うための方法、デバイス及びシステム
JP2008533466A (ja) * 2005-03-11 2008-08-21 ヘモク アクチボラゲット 白血球の体積当たりの計数を行うための方法、デバイス及びシステム
US7521243B2 (en) 2005-03-11 2009-04-21 Hemocue Ab Enumeration of white blood cells
CN101137904B (zh) * 2005-03-11 2013-06-19 海莫库公司 用于白血细胞的体积测定计数的方法、装置和系统
NO340137B1 (no) * 2005-03-11 2017-03-13 Hemocue Ab En fremgangsmåte, anordning og system for volumetrisk opptelling av hvite blodceller
WO2006096126A1 (fr) * 2005-03-11 2006-09-14 Hemocue Ab Procede, dispositif et systeme de numeration volumetrique de globules blancs
US8092758B2 (en) 2005-03-11 2012-01-10 Hemocue Ab Method, device and system for volumetric enumeration of white blood cells
WO2008010761A1 (fr) 2006-07-19 2008-01-24 Hemocue Ab appareil de mesure, procédé et programme informatique
US8224058B2 (en) 2006-07-19 2012-07-17 Hemocue Ab Measurement apparatus, method and computer program
US9494509B2 (en) 2006-11-03 2016-11-15 Los Alamos National Security, Llc System and method for measuring particles in a sample stream of a flow cytometer using low-power laser source
EP1947441A3 (fr) * 2007-01-17 2011-08-24 HemoCue AB Appareil pour déterminer les positions d'objets contenus dans un échantillon
WO2008088249A1 (fr) * 2007-01-17 2008-07-24 Hemocue Ab Appareil de détermination de positions d'objets contenus dans un échantillon
EP1947441A2 (fr) * 2007-01-17 2008-07-23 Hemocue AB Appareil pour déterminer les positions d'objets contenus dans un échantillon
US8873051B2 (en) 2007-04-02 2014-10-28 Life Technologies Corporation Methods and systems for controlling the flow of particles for detection
US8846408B2 (en) 2007-04-02 2014-09-30 Life Technologies Corporation Particle analyzing systems and methods using acoustic radiation pressure
US8900870B2 (en) 2007-04-02 2014-12-02 Life Technologies Corporation Methods for fusing cells using acoustic radiation pressure
US10969325B2 (en) 2007-04-02 2021-04-06 Life Technologies Corporation Particle analyzing systems and methods using acoustic radiation pressure
US10254212B2 (en) 2007-04-02 2019-04-09 Life Technologies Corporation Particle analyzing systems and methods using acoustic radiation pressure
US9134271B2 (en) 2007-04-02 2015-09-15 Life Technologies Corporation Particle quantifying systems and methods using acoustic radiation pressure
US9476855B2 (en) 2007-04-02 2016-10-25 Life Technologies Corporation Particle analyzing systems and methods using acoustic radiation pressure
US8863958B2 (en) 2007-04-09 2014-10-21 Los Alamos National Security, Llc Apparatus for separating particles utilizing engineered acoustic contrast capture particles
US9909117B2 (en) 2007-04-09 2018-03-06 Los Alamos National Security, Llc Systems and methods for separating particles utilizing engineered acoustic contrast capture particles
US9733171B2 (en) 2007-04-09 2017-08-15 Los Alamos National Security, Llc Acoustic concentration of particles in fluid flow
US7837040B2 (en) 2007-04-09 2010-11-23 Los Alamos National Security, Llc Acoustic concentration of particles in fluid flow
US9339744B2 (en) 2007-04-09 2016-05-17 Los Alamos National Security, Llc Apparatus for separating particles utilizing engineered acoustic contrast capture particles
US8932520B2 (en) 2007-10-24 2015-01-13 Los Alamos National Security, Llc Method for non-contact particle manipulation and control of particle spacing along an axis
US9488621B2 (en) 2007-12-19 2016-11-08 Los Alamos National Security, Llc Particle analysis in an acoustic cytometer
US9038467B2 (en) 2007-12-19 2015-05-26 Los Alamos National Security, Llc Particle analysis in an acoustic cytometer
US11287362B2 (en) 2007-12-19 2022-03-29 Triad National Security, Llc Particle analysis in an acoustic cytometer
US11287363B2 (en) 2007-12-19 2022-03-29 Triad National Security, Llc Particle analysis in an acoustic cytometer
WO2009091925A2 (fr) * 2008-01-16 2009-07-23 Life Technologies Corporation Système et procédé pour matériel de concentration acoustique et mises en œuvre
CN104949909A (zh) * 2008-01-16 2015-09-30 生命技术公司 用于以声学方式集中的硬件与实现的系统和方法
EA021093B9 (ru) * 2008-01-16 2016-01-29 Лайф Текнолоджиз Корпорейшн Устройство и способ акустического фокусирования частиц
EA021093B1 (ru) * 2008-01-16 2015-04-30 Лайф Текнолоджиз Корпорейшн Устройство и способ акустического фокусирования частиц
US10976234B2 (en) 2008-01-16 2021-04-13 Life Technologies Corporation System and method for acoustic focusing hardware and implementations
WO2009091925A3 (fr) * 2008-01-16 2009-10-08 Life Technologies Corporation Système et procédé pour matériel de concentration acoustique et mises en œuvre
US20230168175A1 (en) * 2008-01-16 2023-06-01 Life Technologies Corporation System And Method For Acoustic Focusing Hardware And Implementations
WO2012059784A1 (fr) 2010-11-03 2012-05-10 Reametrix Inc Procédé et dispositif de mesure de fluorescence d'échantillons
US9523640B2 (en) 2010-11-03 2016-12-20 Reametrix, Inc. Method of fluorescent measurement of samples, and devices therefrom
US20210181085A1 (en) * 2017-10-26 2021-06-17 Essenlix Corporation Rapid measurement of platelets

Also Published As

Publication number Publication date
AU6542196A (en) 1997-02-05

Similar Documents

Publication Publication Date Title
US5547849A (en) Apparatus and method for volumetric capillary cytometry
Welsh et al. A compendium of single extracellular vesicle flow cytometry
US5932428A (en) Method for preparing a sample in a scan capillary for immunofluorescent interrogation
US5556764A (en) Method and apparatus for cell counting and cell classification
US4745285A (en) Multi-color fluorescence analysis with single wavelength excitation
EP1334346B1 (fr) Analyseur de particules ou de cellules et son procede
EP1558934B1 (fr) Procede d'evaluation de particules
US8284384B2 (en) Method and apparatus for analyzing individual cells or particulates using fluorescent quenching and/or bleaching
WO1997002482A1 (fr) Procede et dispositif pour la quantification volumetrique
JP3098273B2 (ja) 尿中の細胞分析装置
CA1309326C (fr) Methode de classification des leucocytes par cytometrie de flux, et reactifs utilises dans le cadre de cette methode
EP0335725A2 (fr) Appareil et méthode de détection de fluorescence ou de diffusion de lumière
Ligler et al. The microflow cytometer
JP2008536093A (ja) 透明媒質及び懸濁媒質内の粒子を特性評価する方法及びデバイス
RU2397494C2 (ru) Способ дискриминации по меньшей мере двух клеточных популяций и его применение
US9933415B2 (en) Internal focus reference beads for imaging cytometry
US20080021674A1 (en) Methods for Enhancing the Analysis of Particle Detection
WO2000071991A1 (fr) Procede et appareil de detection optique dans une profondeur de champ limitee
WO2005096749A2 (fr) Systeme de balayage laser polychrome et procede d'utilisation
WO2005033283A2 (fr) Procedes pour ameliorer l'analyse de detection de particules
Givan Flow cytometry: an introduction
US20200379227A1 (en) Method For Analyzing Fluorescent Particles in an Immunoassay
US20230296591A1 (en) Sample analysis method, sample analyzer, and computer-readable storage medium
CN116438438A (zh) 用于基于流动的单颗粒和/或单分子分析的方法和设备
CN212459331U (zh) 时间分辨流式荧光检测分析装置

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR CA CN CZ EE FI GE HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase